 SAN FRANCISCO, Aug. 31, 2022 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurixs president and chief executive officer, will participate in the following conferences in September: 